Efficacy and Safety of the PCSK9 Inhibitor Evolocumab in Patients with Mixed Hyperlipidemia

Purpose Evolocumab significantly reduces low-density lipoprotein-cholesterol (LDL-C); we investigated its effects on LDL-C lowering in patients with mixed hyperlipidemia. Methods We compared the efficacy and safety of evolocumab in hypercholesterolemic patients selected from the phase 2 and 3 trials...

Full description

Saved in:
Bibliographic Details
Published in:Cardiovascular drugs and therapy 2016-06, Vol.30 (3), p.305-313
Main Authors: Rosenson, Robert S., Jacobson, Terry A., Preiss, David, Djedjos, C. Stephen, Dent, Ricardo, Bridges, Ian, Miller, Michael
Format: Article
Language:English
Subjects:
Adolescent
Adult
Aged
Aged, 80 and over
Antibodies, Monoclonal - adverse effects
Antibodies, Monoclonal - therapeutic use
Anticholesteremic Agents - adverse effects
Anticholesteremic Agents - therapeutic use
Apolipoproteins B - blood
Cardiology
Cholesterol - blood
Double-Blind Method
Ezetimibe - adverse effects
Ezetimibe - therapeutic use
Female
Humans
Hypercholesterolemia - blood
Hypercholesterolemia - drug therapy
Male
Medicine
Medicine & Public Health
Middle Aged
Original
Original Article
Proprotein Convertase 9 - antagonists & inhibitors
Treatment Outcome
Triglycerides - blood
Young Adult
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Purpose Evolocumab significantly reduces low-density lipoprotein-cholesterol (LDL-C); we investigated its effects on LDL-C lowering in patients with mixed hyperlipidemia. Methods We compared the efficacy and safety of evolocumab in hypercholesterolemic patients selected from the phase 2 and 3 trials who had fasting triglyceride levels ≥1.7 mmol/L (150 mg/dL elevated triglycerides) and
ISSN:0920-3206
1573-7241
DOI:10.1007/s10557-016-6666-1